Cargando…

A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee

In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over des...

Descripción completa

Detalles Bibliográficos
Autores principales: Camfield, David A., Silber, Beata Y., Scholey, Andrew B., Nolidin, Karen, Goh, Antionette, Stough, Con
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857311/
https://www.ncbi.nlm.nih.gov/pubmed/24349389
http://dx.doi.org/10.1371/journal.pone.0082897
_version_ 1782295148916375552
author Camfield, David A.
Silber, Beata Y.
Scholey, Andrew B.
Nolidin, Karen
Goh, Antionette
Stough, Con
author_facet Camfield, David A.
Silber, Beata Y.
Scholey, Andrew B.
Nolidin, Karen
Goh, Antionette
Stough, Con
author_sort Camfield, David A.
collection PubMed
description In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, with cognitive and mood assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome measure was accuracy in Rapid Visual Information Processing (RVIP). Secondary cognitive outcome measures included RVIP reaction time as well as Inspection time (IT), Jensen Box decision/reaction times, serial subtraction and N-Back working memory. Secondary mood measures included Bond-Lader and caffeine Research visual analogue scales (VAS). No significant treatment effects were found for the primary outcome measure, although significant effects were found amongst secondary measures. Overall, CGA in isolation was not found to significantly improve cognitive function relative to placebo whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison to placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) in comparison to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve alertness on both the Bond-Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine Research VAS relative to CGA (t=3.09, p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. Both the GB and CGA were also found to significantly improve symptoms of headache at 120 minutes relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04 respectively), whilst there was a trend towards a reduction in jitteriness with GB and CGA in comparison to placebo at 40 minutes post-dose (t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the improvements in mood observed with GB, but not the improvements in cognitive function, are likely to some extent to be attributable to CGAs. Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12611000067976 www.anzctr.org.au
format Online
Article
Text
id pubmed-3857311
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38573112013-12-13 A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee Camfield, David A. Silber, Beata Y. Scholey, Andrew B. Nolidin, Karen Goh, Antionette Stough, Con PLoS One Research Article In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, with cognitive and mood assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome measure was accuracy in Rapid Visual Information Processing (RVIP). Secondary cognitive outcome measures included RVIP reaction time as well as Inspection time (IT), Jensen Box decision/reaction times, serial subtraction and N-Back working memory. Secondary mood measures included Bond-Lader and caffeine Research visual analogue scales (VAS). No significant treatment effects were found for the primary outcome measure, although significant effects were found amongst secondary measures. Overall, CGA in isolation was not found to significantly improve cognitive function relative to placebo whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison to placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) in comparison to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve alertness on both the Bond-Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine Research VAS relative to CGA (t=3.09, p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. Both the GB and CGA were also found to significantly improve symptoms of headache at 120 minutes relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04 respectively), whilst there was a trend towards a reduction in jitteriness with GB and CGA in comparison to placebo at 40 minutes post-dose (t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the improvements in mood observed with GB, but not the improvements in cognitive function, are likely to some extent to be attributable to CGAs. Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12611000067976 www.anzctr.org.au Public Library of Science 2013-12-09 /pmc/articles/PMC3857311/ /pubmed/24349389 http://dx.doi.org/10.1371/journal.pone.0082897 Text en © 2013 Camfield et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Camfield, David A.
Silber, Beata Y.
Scholey, Andrew B.
Nolidin, Karen
Goh, Antionette
Stough, Con
A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title_full A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title_fullStr A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title_full_unstemmed A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title_short A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
title_sort randomised placebo-controlled trial to differentiate the acute cognitive and mood effects of chlorogenic acid from decaffeinated coffee
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857311/
https://www.ncbi.nlm.nih.gov/pubmed/24349389
http://dx.doi.org/10.1371/journal.pone.0082897
work_keys_str_mv AT camfielddavida arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT silberbeatay arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT scholeyandrewb arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT nolidinkaren arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT gohantionette arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT stoughcon arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT camfielddavida randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT silberbeatay randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT scholeyandrewb randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT nolidinkaren randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT gohantionette randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee
AT stoughcon randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee